Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Nurix Therapeutics, Inc. (NRIX) announced participation in upcoming healthcare conferences by key executives, including fireside chats and one-on-one meetings. The company aims to showcase its innovative approach in developing targeted protein modulation drugs for cancer and inflammatory diseases.
  • None.
  • None.

SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, Nurix’s chief financial officer, and Jason Kantor, Ph.D., Nurix’s chief business officer, will participate in the following conferences in April:

  • 23rd Annual Needham Virtual Healthcare Conference
    Fireside chat: Arthur T. Sands, M.D, Ph.D.
    Monday, April 8, 2024, from 11:00 – 11:40 a.m. ET
  • Stifel 2024 Virtual Targeted Oncology Forum
    Fireside chat: Hans van Houte and Jason Kantor, Ph.D.
    Tuesday, April 16, 2024, from 1:00 – 1:25 p.m. ET
  • Piper Sandler Spring Biopharma Symposium (Boston, MA)
    One-on-one meetings only: Wednesday, April 17, 2024

Both fireside chats will be webcast live and may be accessed via links in the Investors section of the Nurix website under Events and Presentations. The archived webcasts will be available on the Nurix website for 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit


Jason Kantor, Ph.D.
Nurix Therapeutics

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors

Aljanae Reynolds
Wheelhouse Life Science Advisors

Arthur T. Sands will participate on Monday, April 8, 2024, from 11:00 – 11:40 a.m. ET.

Hans van Houte and Jason Kantor, Ph.D., will participate in the fireside chat on Tuesday, April 16, 2024, from 1:00 – 1:25 p.m. ET.

The webcasts can be accessed via links in the Investors section of the Nurix website under Events and Presentations.

The archived webcasts will be available for 30 days after the event on the Nurix website.
Nurix Therapeutics Inc


NRIX Rankings

NRIX Latest News

NRIX Stock Data

Pharmaceutical Preparation Manufacturing
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing

About NRIX

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe